<i id='D1141DDF98'><strike id='D1141DDF98'><tt id='D1141DDF98'><pre id='D1141DDF98'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Alkermes shareholders re 
PhRMA lawsuit over Medicare drug price negotiation tossed 
Trump demands the U.S. pay no more for drugs than other countries … again 
What the airline industry can learn from medicine 
Duchenne breakthrough therapy leaves behind pioneering families 
Infectious disease expert Jeanne Marrazzo assumes Fauci role 
Tori Bowie and the unacceptable rates of Black maternal death 
Biogen Alzheimer’s drug launch off to slow start 
As demand for Covid shots wanes, Moderna seeks its next success 
'Revelatory' study finds a smoking impact that remains after quitting 
The Supreme Court will review a ruling striking down a domestic violence federal gun ban 
BioAge raises $170M for combination therapy with Zepbound 
In age of alternative facts, a scholarly course on calling out crap 
What we’ve learned from the Aduhelm mess 
Medicare details structure of new drug price negotiation program 
